Estabelecimento de organoides tumorais derivados do câncer de pâncreas e fibroblastos a partir de tecido fresco

6.7K visualizações

Citado por 5

07:31 min.

26 de maio de 2023

10.3791/65229-v

26 de maio de 2023

6.7K visualizações

¹Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), ²The Biomedical Research Network in Cancer (CIBERONC), ³Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS), ⁴Faculty of Medicine, University of Alcalá de Henares, ⁵Institute of Tissue Medicine and Pathology, University of Bern, ⁶Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, ⁷Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), ⁸Department of Surgical Oncology, National Cancer Institute, Slovak Medical University, ⁹Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal, ¹⁰Department of Pathology, Hospital Universitario Ramón y Cajal, ¹¹Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, ¹²Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), ¹³Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS

^* These authors contributed equally

Os organoides tumorais revolucionaram a pesquisa do câncer e a abordagem da medicina personalizada. Eles representam um modelo de tumor clinicamente relevante que permite aos pesquisadores ficar um passo à frente do tumor na clínica. Este protocolo estabelece organoides tumorais a partir de amostras de tecido tumoral pancreático fresco e xenoenxertos derivados do paciente de origem adenocarcinoma pancreático.